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Introduction
Experience from prior military conflicts and early data from Iraq and Afghanistan suggest that a significant percentage of troops on hazardous deployments will develop posttraumatic stress disorder (PTSD). This is one of the most common, debilitating, and chronic psychological disorders diagnosed among veterans. A large body of evidence in PTSD now documents dysfunction of the hormone system that coordinates the biological response to stress (the hypothalamicpituitary-adrenal [HPA] axis). However, existing studies typically involve participants who have suffered from the disorder for many years, and information on biological processes occurring early in the disorder is lacking. In addition, specific genes that regulate HPA axis function have recently been identified in humans. Genes that are involved in the processing of emotions and cognition may also be involved in the pathogenesis of PTSD. In recent years investigators have begun to identify some of the relevant genes, and a few recent studies have identified specific gene-environment interactions that appear to confer risk for mood and anxiety disorders. The objective of this proposal is to study these biomarkers of risk in a carefully assessed population of military personnel who have recently returned from war zones. This study will enroll a target sample of 300 men and women who have recently returned from hazardous deployment in a war zone and are undergoing a comprehensive assessment of symptoms and stressors in a related 12-month longitudinal study. Samples of saliva will be obtained for analysis of DNA and candidate genes as well as hormone concentrations (cortisol). Hormone and genetic data will be used to predict the development of PTSD and chronic PTSD. In addition, interactions of trauma severity and other stressors as well as social supports with the biological factors will be examined. Findings of this study will contribute to knowledge about the biomarkers of risk for PTSD and will therefore increase our knowledge of the disease process and may help us to identify individuals who are at highest risk for PTSD.
• Started to run assays and do preliminary analyses • Started to clean data • Renewed IRB approval
Reportable Outcomes
The data presented below reflect preliminary analyses with the available data.
Cortisol: Cortisol data for 93 subjects are available presently for analysis. A repeated measures analysis of the effects of trauma exposure (Hoge scale) and current PTSD symptoms, controlling for effects of age, showed a significant effect of PTSD symptoms over time (F(4, 85) = 2.95, p=.025) and a significant interaction of PTSD symptoms and trauma exposure over time (F4, 85) = 6.85, p<.001). As shown in the figure to the right, among subjects with moderate trauma exposure (Hoge score at or above the median of 10), those with PTSD symptoms had higher cortisol concentrations upon awakening and 30-minutes following awakening.
Genetics: Preliminary data -genetics: We have extracted DNA samples from the first 148 samples and genotyped them for the 5HTTLPR (triallelic data), COMT rs4680 SNP and, DAT VNTR. Genotype frequencies were SS: n = 33 (22.3%), SLG: n = 0 (0%), LGLG: n = 0 (0%), SLA: n = 74 (50%), LGLA: n = 9 (6.1%), and LALA: n = 32 (21.6%). COMT rs4680 genotype frequencies were: Met/Met: n = 37 (32%), Val/Met: n = 51 (44.7%), Val/Val: n = 26 (23%). DAT VNTR genotype frequencies were: 9/9: n = 10 (6.7%), 10/9: n = 60 (40.5%), 10/10: n = 78 (52.7%). Initial analyses did not reveal any significant associations between genotype and PTSD diagnosis. This may be due to insufficient power, so the next steps will be to genotype additional samples. Further analyses will examine the importance of comorbid diagnoses, degree of trauma exposure, and will include potentially critical covariates such as childhood maltreatment. . Tyrka, A., Smith, G.P., and Gibbs, J. SCH 23390 inhibits intake of sucrose more during independent ingestion than during intraoral infusion in rats as early as postnatal day 7. Society for Neuroscience, 1990.
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